Aesther is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Its principals possess public and private market investing experience and operational knowledge to bring value added benefits to Ocean Biomedical. The Aesther team has substantial experience investing in and operating businesses in multiple sectors, as well as a significant long-term track record in creatively structuring transactions to unlock and maximize value.
Company profile
Ticker
AEHA, AEHAU
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
871309280
AEHA stock data
Latest filings (excl ownership)
425
Business combination disclosure
1 Feb 23
8-K
Regulation FD Disclosure
1 Feb 23
425
Business combination disclosure
30 Jan 23
8-K
Regulation FD Disclosure
30 Jan 23
DEFR14A
Revised proxy
25 Jan 23
425
Business combination disclosure
24 Jan 23
8-K
Ocean Biomedical Provides Corporate Update and Company Summary
24 Jan 23
425
Business combination disclosure
13 Jan 23
8-K
Regulation FD Disclosure
13 Jan 23
DEF 14A
Definitive proxy
12 Jan 23
Latest ownership filings
SC 13G/A
BOOTHBAY FUND MANAGEMENT, LLC
31 Jan 23
SC 13G
MIZUHO FINANCIAL GROUP INC
14 Feb 22
SC 13G/A
Saba Capital Management, L.P.
14 Feb 22
SC 13G
ATW SPAC MANAGEMENT LLC
14 Feb 22
SC 13G/A
Beryl Capital Management LLC
11 Feb 22
SC 13G
Shaolin Capital Management LLC
11 Feb 22
SC 13G
Aesther Healthcare Sponsor, LLC
7 Feb 22
SC 13G
Hudson Bay Capital Management LP
7 Feb 22
SC 13G
Weiss Asset Management LP
7 Feb 22
SC 13G
BOOTHBAY FUND MANAGEMENT, LLC
4 Feb 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
Institutional ownership, Q3 2022
| 13F holders | Current |
|---|---|
| Total holders | 44 |
| Opened positions | 22 |
| Closed positions | 7 |
| Increased positions | 14 |
| Reduced positions | 3 |
| 13F shares | Current |
|---|---|
| Total value | 701.58 mm |
| Total shares | 14.05 mm |
| Total puts | 0.00 |
| Total calls | 14.08 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Aesther Healthcare Sponsor | 2.63 mm | $26.22 mm |
| Polar Asset Management Partners | 825.00 k | $8.41 mm |
| Shaolin Capital Management | 796.90 k | $8.12 mm |
| MFG Mizuho Financial | 750.00 k | $7.49 mm |
| Saba Capital Management | 733.93 k | $7.48 mm |
| Boothbay Fund Management | 601.22 k | $6.13 mm |
| Atw Spac Management | 600.00 k | $6.11 mm |
| Weiss Asset Management | 599.47 k | $6.11 mm |
| Vivaldi Asset Management | 568.57 k | $5.79 mm |
| Hudson Bay Capital Management | 528.00 k | $5.38 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Nov 21 | Aesther Healthcare Sponsor | Class B common stock Class A common stock | Other | Dispose J | No | No | 0 | 250,000 | 0.00 | 2,625,000 |
| 3 Nov 21 | Ajjarapu Surendra K | Class B common stock Class A common stock | Other | Dispose J | Yes | No | 0 | 250,000 | 0.00 | 2,625,000 |
News
Ocean Biomedical And Aesther Healthcare Acquisition Corp. Announce Publication Of Discovery Data For A Major Anti-Tumor Pathway In Malignant Melanoma And Other Cancers
30 Jan 23
EXCLUSIVE: Aesther Healthcare's Merger Partner Ocean Biomedical Unveils Discovery Data For Major Anti-Tumor Pathway In Skin Cancer
30 Jan 23
Aesther Healthcare Acquisition Corp. Announces Intention To Extend Period To Consummate Business Combination
13 Dec 22
Press releases
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Measures regarding Excise Tax
1 Feb 23
Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers
30 Jan 23
Ocean Biomedical Provides Corporate Update and Company Summary
24 Jan 23
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc.
13 Jan 23
Malaria Pipeline Clinical Trials Featuring 35+ companies| DelveInsight
4 Jan 23